Chardan Capital Brokers Decrease Earnings Estimates for LXEO

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at Chardan Capital reduced their FY2024 EPS estimates for Lexeo Therapeutics in a research report issued on Wednesday, November 13th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings of ($3.03) per share for the year, down from their prior estimate of ($2.93). Chardan Capital currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.05) per share. Chardan Capital also issued estimates for Lexeo Therapeutics’ FY2025 earnings at ($2.30) EPS.

A number of other equities analysts also recently commented on LXEO. Leerink Partners lowered their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. Finally, HC Wainwright boosted their target price on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Buy” and an average price target of $22.71.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock opened at $6.65 on Monday. The company has a current ratio of 5.95, a quick ratio of 9.38 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average price of $9.01 and a 200 day moving average price of $12.23. The company has a market cap of $219.92 million and a P/E ratio of -2.10. Lexeo Therapeutics has a 12 month low of $6.65 and a 12 month high of $22.33.

Insider Buying and Selling at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the company’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the completion of the transaction, the chief executive officer now owns 120,695 shares in the company, valued at $977,629.50. This represents a 3.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 12,500 shares of company stock worth $113,300 over the last 90 days. Corporate insiders own 4.50% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in LXEO. BNP Paribas Financial Markets purchased a new stake in shares of Lexeo Therapeutics in the first quarter valued at about $75,000. Vanguard Group Inc. raised its holdings in shares of Lexeo Therapeutics by 15.8% in the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after buying an additional 65,573 shares during the last quarter. American International Group Inc. purchased a new stake in shares of Lexeo Therapeutics in the first quarter valued at about $79,000. Janus Henderson Group PLC raised its holdings in shares of Lexeo Therapeutics by 9.0% in the first quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock valued at $39,802,000 after buying an additional 210,047 shares during the last quarter. Finally, Artal Group S.A. raised its holdings in shares of Lexeo Therapeutics by 32.9% in the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock valued at $12,571,000 after buying an additional 198,281 shares during the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.